Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis
Open Access
- 6 November 2019
- journal article
- research article
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 40 (11) , 1804-1810
Abstract
BACKGROUND AND PURPOSE: Diffuse midline gliomas with histone H3 K27M mutation are biologically aggressive tumors with poor prognosis defined as a new diagnostic entity in the 2016 World Health Organization Classification of Tumors of the Central Nervous System. There are no qualitative imaging differences (enhancement, border, or central necrosis) between histone H3 wildtype and H3 K27M-mutant diffuse midline gliomas. Herein, we evaluated the utility of diffusion-weighted imaging to distinguish H3 K27M-mutant from histone H3 wildtype diffuse midline gliomas. MATERIALS AND METHODS: We identified 31 pediatric patients (younger than 21 years of age) with diffuse gliomas centered in midline structures that had undergone assessment for histone H3 K27M mutation. We measured ADC within these tumors using a voxel-based 3D whole-tumor measurement method. RESULTS: Our cohort included 18 infratentorial and 13 supratentorial diffuse gliomas centered in midline structures. Twenty-three (74%) tumors carried H3-K27M mutations. There was no difference in ADC histogram parameters (mean, median, minimum, maximum, percentiles) between mutant and wild-type tumors. Subgroup analysis based on tumor location also did not identify a difference in histogram descriptive statistics. Patients who survived 1 year (1.46 × 10−3mm2/s; 95% CI, 1.19–1.67; P < .06). Average ADC values for diffuse midline gliomas were 1.28 × 10−3mm2/s (95% CI, 1.21–1.34) and 0.86 × 10−3mm2/s (95% CI, 0.69–1.01) for hemispheric glioblastomas with P < .05. CONCLUSIONS: Although no statistically significant difference in diffusion characteristics was found between H3-K27M mutant and H3 wildtype diffuse midline gliomas, lower diffusivity corresponds to a lower survival rate at 1 year after diagnosis. These findings can have an impact on the anticipated clinical course for this patient population and offer providers and families guidance on clinical outcomes.Keywords
Funding Information
- Foundation for the National Institutes of Health (DP5OD021403)
- Clinical Center (NIH T32 Grant 5T32EB001631-12)
- NIH T32 (NIH T32 Grant #T32EB001631)
- American Society of Neuroradiology Fellow Award 2018
- National Center for Advancing Translational Sciences (UCSF-CTSI Grant KL2TR000143)
This publication has 13 references indexed in Scilit:
- 2016 World Health Organization Classification of Central Nervous System Tumors: An Era of Molecular BiologyWorld Neurosurgery, 2016
- Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine gliomaNature Communications, 2016
- Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor ConsortiumNeuro-Oncology, 2015
- Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypesActa Neuropathologica, 2015
- Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markersActa Neuropathologica, 2015
- Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of GlioblastomaCancer Cell, 2012
- Discrimination of paediatric brain tumours using apparent diffusion coefficient histogramsEuropean Radiology, 2011
- Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated GlioblastomaAmerican Journal of Neuroradiology, 2011
- ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade gliomaNeuroradiology, 2010
- Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab TreatmentRadiology, 2009